The recent advances in understanding the immunopathology of rapid-onset ACD have uncovered several promising therapeutic targets aimed at mitigating the immune responses driven by allergen-specific CD8+ TRM cells and their recruitment of neutrophils. Here, CD8A is linked to granular corneal dystrophy type II.